Abstract:4055 Background: First-line chemotherapy in metastatic gastric cancer, either doublet or triplet-regiment, the average OS is less than one year. Anti-VEGF target therapy is proven to be effective both in second and third line settings. As for apatinib, which is the tyrosine kinase inhibitor showed highly affinity for VEGFR2, is permitted by SFDA to be used in the third line treatment of gastric cancer since September 2014. The post-market stage IV clinic trial Ahead-G201 further confirmed it can improve the OS in chemotherapy-refractory gastric cancer. What’s more, apatinib could reverse paclitaxel resistance and improve the R0 resection rate in conversion of unresected gastric cancer in neoadjuvant settings. However, the safety and efficacy of apatinib in combination with docetaxel plus S1 in the first line treatment of metastatic gastric cancer is unknown and worthy of investigation. Methods: With expectation to improve PFS from 5.3m (the START Study) to 7m, this investigator-initiated, single arm, multi-center, registered phase II prospective study was designed to enroll 48 eligible patients diagnosed with metastatic gastric cancer. Each participant was expected to finish six cycles of chemotherapy plus apatinib (docetaxel 75mg/m2, d1, Q3W; S1 according to BSA: <1.25 40mg po bid; 1.25̃1.5 50mg po bid; >1.5 60mg po bid; d1-14, Q3W; apatinib 500mg po qd). The toxicity was determined according to CTCAE 4.0. Efficacy assessed every two cycles (6 weeks) during the study and every 2 months during the follow-up period. The primary endpoint was PFS. The secondary endpoint was OS, ORR, and DCR. The tumor response was determined according to RECIST 1.1 criteria. Results: Baseline characteristics (FAS population): From July 2017 to December 2020, 45 patients from 5 centers across Hubei province were enrolled. Among them, 44 are eligible for analysis. There are 15 females and 30 males, median age 55 years old, median metastasis sites is 2, yet 63.6% of them have involved at least 2 organs. Safety: 90.91% patients reported adverse events (AEs). The incidence of grade 3-4 AEs was 47.73%. Main 3-4 AEs were oral ulceration (13.64%), leucopenia (13.64%), neutropenia (13.64%), hand-foot syndrome (6.82%), hypertension (6.82%), and thrombocytopenia (6.82%). Efficacy: By Jan 31th, 2021, 44 patients were evaluable for response and survival, 26 of them achieved partial response (PR), 9 achieved stable disease (SD), and 8 experienced progression disease (PD). The ORR is 60.47%, the DCR is 81.4%. Median PFS is 7.46m, median OS is 12.42m. So we closed the study in advance. Conclusions: Adding apatinib to standard DS chemotherapy as the first line treatment would be well tolerant in patients with metastatic gastric cancer, the spectrum of toxicity were not exceeding expectation. This modality also exhibits prolonged PFS, which might provide an alternative therapeutic strategy for metastatic gastric cancer. Clinical trial information: NCT03154983.

Phase I trial of apatinib and paclitaxel+oxaliplatin+5‐FU/levoleucovorin for treatment‐naïve advanced gastric cancer

Efficacy and Safety for Apatinib Combined with Oxaliplatin and S1 in Initially Treated Metastatic Gastric Cancer: A Single-Center Observational Study.

A Phase I Dose Escalation Study of Apatinib Combinated with Docetaxel As Second-line Therapy for Advanced Gastric Carcinoma

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients with Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

Apatinib in combination with docetaxel and S1 chemotherapy in the first-line treatment of metastatic gastric cancer.

Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results from a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial.

Apatinib in Combination with Docetaxol and S1 Chemotherapy in the First-Line Treatment of Metastatic Gastric Cancer

The Multicenter, Phase Ii Prospective Study of Paclitaxel Plus Capecitabine As First-Line Chemotherapy in Advanced Gastric Carcinoma

Apatinib combined with paclitaxel-based chemotherapy in patients with taxane-resistant advanced gastric cancer: a single-arm exploratory study

A Phase Ii, Open-Label, Multicenter, Prospective Study of Paclitaxel Plus Capecitabine with Subsequent Capecitabine Maintenance Therapy As First-Line Treatment for Metastatic or Recurrent Gastric Cancer

Multicenter Phase II Study of Apatinib Treatment for Metastatic Gastric Cancer after Failure of Second-Line Chemotherapy.

P3.02c-025 Safety and Efficacy of Apatinib in Patients with Previously Heavily Treated Advanced Non-Squamous Non-Small-Cell Lung Cancer

A multicenter, open-label phase II trial of second-line apatinib plus irinotecan in patients with advanced gastric cancer.

Phase I Study of Apatinib Combined with Docetaxel in EGFR-negative Advanced Non-Small Cell Lung Cancer (NSCLC).

Apatinib Plus Sox Regimen As Neoadjuvant Chemotherapy For Locally Advanced Gastric Cancer: A Phase Ii Study.

Clinical Study on the Efficacy of Apatinib Treatment for Advanced Ovarian Cancer after Second-Line Chemotherapy Failure

Safety and efficacy of apatinib in combination with chemotherapy with or without immunotherapy versus chemotherapy alone as first-line treatment for advanced gastric cancer

P1.01-109 Phase I Study of Apatinib Plus Gefitinib As First-Line Therapy in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer

A Prospective, Randomized, Controlled, Multicenter Study of Apatinib Combined with S-1 Plus Docetaxel As Adjuvant Therapy for Locally Advanced Gastric Cancer.

Apatinib In The Treatment Of Non-Operable Or Advanced Gastric Cancer: Evidence Of Efficacy And Safety In A Real-World Study.

Clinical effectiveness of apatinib at different doses in patients with advanced gastric cancer as the third-line or further treatment: Results from a post-marketing phase IV study.